161 related articles for article (PubMed ID: 35986430)
21. Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas.
Lekanne Deprez RH; Bianchi AB; Groen NA; Seizinger BR; Hagemeijer A; van Drunen E; Bootsma D; Koper JW; Avezaat CJ; Kley N
Am J Hum Genet; 1994 Jun; 54(6):1022-9. PubMed ID: 7911002
[TBL] [Abstract][Full Text] [Related]
22. Generation of Noninvasive, Quantifiable, Orthotopic Animal Models for NF2-Associated Schwannoma and Meningioma.
Burns SS; Chang LS
Methods Mol Biol; 2016; 1427():59-72. PubMed ID: 27259921
[TBL] [Abstract][Full Text] [Related]
23. Pediatric cerebellopontine angle and internal auditory canal tumors: clinical article.
Holman MA; Schmitt WR; Carlson ML; Driscoll CL; Beatty CW; Link MJ
J Neurosurg Pediatr; 2013 Oct; 12(4):317-24. PubMed ID: 23909617
[TBL] [Abstract][Full Text] [Related]
24. Recurrent YAP1 and MAML2 Gene Rearrangements in Retiform and Composite Hemangioendothelioma.
Antonescu CR; Dickson BC; Sung YS; Zhang L; Suurmeijer AJH; Stenzinger A; Mechtersheimer G; Fletcher CDM
Am J Surg Pathol; 2020 Dec; 44(12):1677-1684. PubMed ID: 32991341
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.
Laraba L; Hillson L; de Guibert JG; Hewitt A; Jaques MR; Tang TT; Post L; Ercolano E; Rai G; Yang SM; Jagger DJ; Woznica W; Edwards P; Shivane AG; Hanemann CO; Parkinson DB
Brain; 2023 Apr; 146(4):1697-1713. PubMed ID: 36148553
[TBL] [Abstract][Full Text] [Related]
26. Renal Cell Carcinoma Unclassified with Medullary Phenotype in a Patient with Neurofibromatosis Type 2.
Sarkar S; Throckmorton W; Bingham R; Msaouel P; Genovese G; Slopis J; Rao P; Sadighi Z; Herzog CE
Curr Oncol; 2023 Mar; 30(3):3355-3365. PubMed ID: 36975468
[TBL] [Abstract][Full Text] [Related]
27. Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.
; Allaway R; Angus SP; Beauchamp RL; Blakeley JO; Bott M; Burns SS; Carlstedt A; Chang LS; Chen X; Clapp DW; Desouza PA; Erdin S; Fernandez-Valle C; Guinney J; Gusella JF; Haggarty SJ; Johnson GL; La Rosa S; Morrison H; Petrilli AM; Plotkin SR; Pratap A; Ramesh V; Sciaky N; Stemmer-Rachamimov A; Stuhlmiller TJ; Talkowski ME; Welling DB; Yates CW; Zawistowski JS; Zhao WN
PLoS One; 2018; 13(6):e0197350. PubMed ID: 29897904
[TBL] [Abstract][Full Text] [Related]
28. Infratentorial meningioma in an 8-year-old child as first sign of neurofibromatosis type 2.
Stettner GM; Rostasy KM; Ludwig HC; Merkler D; Fahsold R; Gärtner J
Neuropediatrics; 2007 Feb; 38(1):29-31. PubMed ID: 17607601
[TBL] [Abstract][Full Text] [Related]
29. Rates of loss of heterozygosity and mitotic recombination in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis schwannomas.
Hadfield KD; Smith MJ; Urquhart JE; Wallace AJ; Bowers NL; King AT; Rutherford SA; Trump D; Newman WG; Evans DG
Oncogene; 2010 Nov; 29(47):6216-21. PubMed ID: 20729918
[TBL] [Abstract][Full Text] [Related]
30. Contiguous conventional and plexiform schwannomas. Report of two cases.
White JB; Scheithauer BW; Amrami KK; Babovic-Vuksanovic D; Spinner RJ
J Neurosurg; 2006 Feb; 104(2):319-24. PubMed ID: 16509508
[TBL] [Abstract][Full Text] [Related]
31. Sustained response to bevacizumab in a patient with mosaic neurofibromatosis type 2 carrying the
Basenach E; Förster A; Raab P; Alzein S; Schmidt G; Krauss JK; Schlegelberger B; Heidenreich F; Auber B; Hartmann C; Wiese B; Weber RG
Clin Neuropathol; 2022; 41(4):162-167. PubMed ID: 35445657
[TBL] [Abstract][Full Text] [Related]
32. The neurofibromatoses. Part 2: NF2 and schwannomatosis.
Lu-Emerson C; Plotkin SR
Rev Neurol Dis; 2009; 6(3):E81-6. PubMed ID: 19898272
[TBL] [Abstract][Full Text] [Related]
33. Neurofibromatosis 2 in the pediatric age group.
Mautner VF; Tatagiba M; Guthoff R; Samii M; Pulst SM
Neurosurgery; 1993 Jul; 33(1):92-6. PubMed ID: 8355853
[TBL] [Abstract][Full Text] [Related]
34. Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis.
Louvrier C; Pasmant E; Briand-Suleau A; Cohen J; Nitschké P; Nectoux J; Orhant L; Zordan C; Goizet C; Goutagny S; Lallemand D; Vidaud M; Vidaud D; Kalamarides M; Parfait B
Neuro Oncol; 2018 Jun; 20(7):917-929. PubMed ID: 29409008
[TBL] [Abstract][Full Text] [Related]
35. Double somatic SMARCB1 and NF2 mutations in sporadic spinal schwannoma.
Paganini I; Capone GL; Vitte J; Sestini R; Putignano AL; Giovannini M; Papi L
J Neurooncol; 2018 Mar; 137(1):33-38. PubMed ID: 29230670
[TBL] [Abstract][Full Text] [Related]
36. Sporadic vestibular schwannoma: a molecular testing summary.
Sadler KV; Bowers NL; Hartley C; Smith PT; Tobi S; Wallace AJ; King A; Lloyd SKW; Rutherford S; Pathmanaban ON; Hammerbeck-Ward C; Freeman S; Stapleton E; Taylor A; Shaw A; Halliday D; Smith MJ; Evans DG
J Med Genet; 2021 Apr; 58(4):227-233. PubMed ID: 32576656
[TBL] [Abstract][Full Text] [Related]
37. Probability of bilateral disease in people presenting with a unilateral vestibular schwannoma.
Evans DG; Lye R; Neary W; Black G; Strachan T; Wallace A; Ramsden RT
J Neurol Neurosurg Psychiatry; 1999 Jun; 66(6):764-7. PubMed ID: 10329751
[TBL] [Abstract][Full Text] [Related]
38. Gastric schwannoma with adjacent external progression harbored aberrant NF2 gene.
Ogasawara N; Sasaki M; Ishiguro H; Itoh Y; Nojiri S; Kubota E; Wada T; Kataoka H; Kuwabara Y; Joh T
Dig Endosc; 2009 Jul; 21(3):192-5. PubMed ID: 19691769
[TBL] [Abstract][Full Text] [Related]
39. The question of familial meningiomas and schwannomas: NF2B or not to be?
King A; Gutmann DH
Neurology; 2000 Jan; 54(1):4-5. PubMed ID: 10636116
[No Abstract] [Full Text] [Related]
40. [Neurofibromatosis type 2].
Goutagny S; Bouccara D; Bozorg-Grayeli A; Sterkers O; Kalamarides M
Rev Neurol (Paris); 2007 Sep; 163(8-9):765-77. PubMed ID: 17878803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
